Diagnostic utility of CYFRA 21-1 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis

International Journal of Biological Markers

Volumn 20, Issue 1, 2005, Pages 43-49

  Szturmowicz, Monika ^a   Tomkowski, W ^a   Fijalkowska, A ^a   Kupis, W ^a   Cieslik A ^a   Demkow, U ^a   Langfort, R ^a   Wiechecka, A ^a   Orlowski, T ^a   Torbicki, A ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Carcinoembryonic antigen; Cytokeratins; Neoplasms; Pericardial effusion

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOCARCINOMA; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CHI SQUARE TEST; COLON CANCER; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PERICARDIAL BIOPSY; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDIOTOMY; PERICARDITIS; PLEURA MESOTHELIOMA; RANK SUM TEST; RECEIVER OPERATING CHARACTERISTIC; RECOGNITION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 20844444908     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.318     Document Type: Article

References (39)

1. Buchanan CL, Sullivan VV, Lampman R, Kulkarni MG. Pericardiocentesis with extended catheter drainage: an effective therapy. Ann Thorac Surg 2003; 76: 817-20.
2. Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002; 77: 429-36.
3. Atar S, Chiu J, Forrester JS, Siegel RJ. Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s? Chest 1999; 116: 1564-9.
4. Keefe DL. Cardiovascular emergencies in the cancer patient. Semin Oncol 2000; 27: 244-55.
5. Sagrista-Sauleda J, Merce J, Permanyer-Miralda G, Soler-Soler J. Clinical clues to the causes of large pericardial effusions. Am J Med 2000; 109: 95-101.
6. Light RW, Rogers JT, Moyers JP, et al. Prevalence and clinical course of pleural effusions at 30 days after coronary artery and cardiac surgery. Am Respir Crit Care Med 2002; 166: 1567-71.
7. Cheung EWY, Ho SA, Tang KKY, Chau ATK, Chiu CSW, Cheung YF. Pericardial effusion after open heart surgery for congenital heart disease. Heart 2003; 89: 780-3.
8. Oh KY, Shimizu M, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of the parietal pericardium: a study of 344 cases (1993-1999). Cardiovasc Pathol 2001; 10: 157-68.
9. Tsang TSM, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Outcomes of clinically significant idiopathic pericardial effusion requiring intervention. Am J Cardiol 2003; 91: 704-7.
10. Vaitkus PT, Herrmann HC, Lewinter MM. Treatment of malignant pericardial effusion. JAMA 1994; 272: 59-64.
11. DeCamp M, Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest 1997; 112: 291s-5s.
12. Allen KB, Penfield Faber L, Warren WH, Shaar CJ. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg 1999; 67: 437-40.
13. Warren WH. Malignancies involving pericardium Semin Thorac Cardiovasc Surg 2000; 12: 119-29.
14. Maish B, Ristic AD. Practical aspects of the management of pericardial disease. Heart 2003; 89: 1096-103.
15. Tomkowski W, Szturmowicz M, Fijalkowska A, Burakowski J, Filipecki S. New approaches to the management and treatment of malignant pericardial effusion. Support Care Cancer 1997; 5: 64-6.
16. Tsang TSM, Seward JB, Barnes ME, et al. Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy. Mayo Clin Proc 2000; 75: 248-53.
17. Moriya T, Takiguchi Y, Tabeta H, et al. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 2000; 83: 858-62.
18. Musch E, Gremmler B, Nitsch J, Rieger J, Malek M, Chrissafidou A. Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion. Oncologie 2003; 26: 135-9.
19. Bardales RH, Stanley MW, Schaefer RF, Liblit RL, Owens RB, Surhland MJ. Secondary pericardial malignancies. Am J Clin Pathol 1996; 106: 29-34.
20. Cullinane CA, Paz IB, Smith D, Carter N, Grannis FW. Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest 2004; 125: 1328-34.
21. Dossios T, Theacos N, Angouras D, Asimacopoulos P. Risk factors affecting the survival of patients with pericardial effusion submitted to subxiphoid pericardiostomy. Chest 2003; 124: 242-6.
22. McDonald JM, Meyers BF, Guthrie TJ, Battafarano RJ, Cooper JD, Patterson GA. Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion. Ann Thorac Surg 2003; 76: 811-6.
23. Wang PC, Yang KY, Chao JY, Ming Liu J, Perng RP, Yen SH. Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest 2000; 118: 744-9.
24. Porte HL, Janecki-Delebecq TJ, Finzi L, Metois DG, Millaire A, Wurtz AJ. Pericardioscopy for primary management of pericardial effusion in cancer patients. Eur J Cardiothorac Surg 1999; 16: 287-91.
25. Koh KK, Kim EJ, Cho CH, et al. Adenosine deaminase and carcinoembryonic antigen in pericardial effusion diagnosis, especially in suspected tuberculous pericarditis. Circulation 1994; 89: 2728-35.
26. Szturmowicz M, Tomkowski W, Fijakowska A, Burakowski J, Sakowicz A, Filipecki S. The role of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) evaluation in pericardial fluid for the recognition of malignant pericarditis. Int J Biol Markers 1997; 12: 96-101.
27. Edoute Y, Malberger E, Kuten A, Ben-Haim SA, Moscovitz M. Cytologic analysis of pericardial effusion complicating extracardiac malignancy. Am J Cardiol 1992; 69: 568-71.
28. Malamou-Mitsi VD, Zioga AP, Agnatis NJ. Diagnostic accuracy of pericardial fluid cytology: an analysis of 53 specimens from 44 consecutive patients. Diagn Cytopathol 1996; 15: 197-204.
29. Wang HJ, Hsu KL, Chiang FT, Tseng CD, Tseng YZ, Liau CS. Technical and prognostic outcomes of double-ballon pericardiotomy for large malignancy-related pericardial effusions. Chest 2002; 122: 893-9.
30. Salama G, Miedouge M, Rouzaud P, et al. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998; 77: 472-6.
31. Huang MS, Jong SB, Tsai MS, et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir Med 1997; 91: 135-42.
32. Hernandez L, Espasa A, Fernandez C, Candela A, Martin C, Romero S. CEA and CA 549 in serum and pleural fluid of patients with pleural effusion. Lung Cancer 2002; 36: 83-9.
33. Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Tumor Biol 2003; 24: 209-18.
34. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001; 31: 9-16.
35. Ryu JS, Lee HJ, Cho JH, Han HS, Lee HL. The implication of elevated carcinoembryonic antigen level in pleural fluid of patients with non-malignant pleural effusion. Respirology 2003; 8: 487-91.
36. Riatawan P, Sangsayan P, Bangpattanasiri K, Rojanaraweewong P. Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respirology 2000; 67: 24-5.
37. Paganuzzi M, Onetto M, Marroni P, et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001; 119: 1138-42.
38. Lai RS, Chen CC, Lee PC, Lu JY. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Jpn J Clin Oncol 1999; 29: 421-4.
39. Ferrer J, Villarino MA, Encabo G, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86: 1488-95.